Predicting the efficacy of monoclonal antibodies against multiple myeloma / 多発性骨髄腫に対する抗体療法の有効性の予測

Description

京都大学 / 新制・論文博士 / 博士(医学) / 乙第13603号 / 論医博第2313号 / 京都大学大学院医学研究科医学専攻 / (主査)教授 森田 智視, 教授 佐藤 俊哉, 教授 永井 純正 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

Links & Downloads

1. http://hdl.handle.net/2433/288434
2. 10.14989/doctor.r13603
3. 14301

Tags

multiple myeloma

κ/λ ratio

β2 microglobulin

lymphocyte counts

monocyte counts

predictive markers

490

Additional Fields

Identifer	oai:union.ndltd.org:kyoto-u.ac.jp/oai:repository.kulib.kyoto-u.ac.jp:2433/288434
Date	25 March 2024
Creators	Shimazu, Yutaka
Contributors	シマヅ, ユタカ
Publisher	Kyoto University, 京都大学
Source Sets	Kyoto University
Language	English
Detected Language	English
Type	doctoral thesis, Thesis or Dissertation
Rights	1.Shimazu Y, Kanda J, Kaneko H, et al. Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide. Therapeutic Advances in Hematology. 2022;13. doi:10.1177/20406207221142487 2.Shimazu, Y., Kanda, J., Kosugi, S. et al. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulin. Scientific Reports 13, 5159 (2023). https://doi.org/10.1038/s41598-023-32426-6
Relation	https://doi.org/10.1177/20406207221142487, https://doi.org/10.1038/s41598-023-32426-6